MedTrace Logo

Assessment of BladderLight SurvEILlance

NCT03427034 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 2100

Last updated 2018-02-09

No results posted yet for this study

Summary

Is BladderLight® (BL) urine testing accurate, as a non-invasive method, to exclude presence of bladder cancer in patients.

Conditions

Interventions

DEVICE

BladderLight®

Using a cell collection device to look for the presence of bladder cancer cells

Sponsors & Collaborators

  • Cytosystems Ltd

    collaborator UNKNOWN

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • kasra Saeb-Parsy, MBBS, FRCSEd · Cambridge University Hospitals NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2020-03-31
Completion
2020-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03427034 on ClinicalTrials.gov